322 related articles for article (PubMed ID: 2196168)
41. Combined alpha- and beta-receptor inhibition in the treatment of hypertension.
Prichard BN
Drugs; 1984; 28 Suppl 2():51-68. PubMed ID: 6151891
[TBL] [Abstract][Full Text] [Related]
42. The role of angiotensin II type 1 receptor antagonists in elderly patients with hypertension.
Thomas GN; Chan P; Tomlinson B
Drugs Aging; 2006; 23(2):131-55. PubMed ID: 16536636
[TBL] [Abstract][Full Text] [Related]
43. Comparative effects of pinacidil and nifedipine in the treatment of arterial hypertension.
Jürgensen HJ
Drugs; 1988; 36 Suppl 7():67-9. PubMed ID: 3076138
[No Abstract] [Full Text] [Related]
44. Pharmacology and structure-activity relationships for KATP modulators: tissue-selective KATP openers.
Atwal KS
J Cardiovasc Pharmacol; 1994; 24 Suppl 4():S12-7. PubMed ID: 7898103
[TBL] [Abstract][Full Text] [Related]
45. Treatment of essential hypertension and hypertension associated with renal impairment with pinacidil: a new vasodilator.
Breen EG; Mulhall D; Keogh JA
Eur J Clin Pharmacol; 1985; 28(4):381-6. PubMed ID: 4029244
[TBL] [Abstract][Full Text] [Related]
46. Clinical pharmacokinetics of pinacidil, a potassium channel opener, in hypertension.
Goldberg MR; Rockhold FW; Thompson WL; DeSante KA
J Clin Pharmacol; 1989 Jan; 29(1):33-40. PubMed ID: 2708546
[TBL] [Abstract][Full Text] [Related]
47. A risk-benefit assessment of losartan potassium in the treatment of hypertension.
Burrell LM
Drug Saf; 1997 Jan; 16(1):56-65. PubMed ID: 9010643
[TBL] [Abstract][Full Text] [Related]
48. Losartan potassium: a review of its pharmacology, clinical efficacy and tolerability in the management of hypertension.
Goa KL; Wagstaff AJ
Drugs; 1996 May; 51(5):820-45. PubMed ID: 8861549
[TBL] [Abstract][Full Text] [Related]
49. Trandolapril. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in essential hypertension.
Wiseman LR; McTavish D
Drugs; 1994 Jul; 48(1):71-90. PubMed ID: 7525196
[TBL] [Abstract][Full Text] [Related]
50. Vasodilators in hypertension--a review with special emphasis on the combined use of vasodilators and beta-adrenoceptor blockers.
Eggertsen R; Hansson L
Int J Clin Pharmacol Ther Toxicol; 1985 Aug; 23(8):411-23. PubMed ID: 2864319
[TBL] [Abstract][Full Text] [Related]
51. Pinacidil: potassium channel openers in the treatment of hypertension. Proceedings of a symposium. Copenhagen, 10-11 March, 1988.
Drugs; 1988; 36 Suppl 7():1-98. PubMed ID: 3254829
[No Abstract] [Full Text] [Related]
52. Effect of antihypertensive agents on quality of life in the elderly.
Fogari R; Zoppi A
Drugs Aging; 2004; 21(6):377-93. PubMed ID: 15084140
[TBL] [Abstract][Full Text] [Related]
53. [Are all antihypertensive drugs renoprotective?].
Wolf S; Risler T
Herz; 2004 May; 29(3):248-54. PubMed ID: 15167950
[TBL] [Abstract][Full Text] [Related]
54. Clevidipine: a review of its use in the management of acute hypertension.
Deeks ED; Keating GM; Keam SJ
Am J Cardiovasc Drugs; 2009; 9(2):117-34. PubMed ID: 19331440
[TBL] [Abstract][Full Text] [Related]
55. Renal effects of pinacidil in hypertensive patients on chronic beta-blocker therapy.
Krusell LR; Christensen CK; Lederballe Pedersen O
Eur J Clin Pharmacol; 1986; 30(6):641-7. PubMed ID: 2876898
[TBL] [Abstract][Full Text] [Related]
56. [The value of angiotensin-converting enzyme inhibitors in the treatment of hypertension].
Klaus D
Z Kardiol; 1988; 77 Suppl 3():73-88. PubMed ID: 3062960
[TBL] [Abstract][Full Text] [Related]
57. Terazosin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in essential hypertension.
Titmarsh S; Monk JP
Drugs; 1987 May; 33(5):461-77. PubMed ID: 2885169
[TBL] [Abstract][Full Text] [Related]
58. Pinacidil. Preclinical investigations.
Ahnfelt-Rønne I
Drugs; 1988; 36 Suppl 7():4-9. PubMed ID: 3076134
[TBL] [Abstract][Full Text] [Related]
59. Introductory remarks: symposium on pinacidil: potassium channel openers in the treatment of hypertension.
Weston AH
Drugs; 1988; 36 Suppl 7():1-3. PubMed ID: 3254828
[No Abstract] [Full Text] [Related]
60. Guanfacine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the treatment of hypertension.
Sorkin EM; Heel RC
Drugs; 1986 Apr; 31(4):301-36. PubMed ID: 3519177
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
